HEPLA: A multicenter study on demographic and disease characteristics of patients with hepatitis C in Latin America

Annals of Hepatology

Roberto J. Carvalho-Filho¹  Fernando Tatsch²  Gabriela Bugarin²  Alma M. Pérez-Ríos³  Luis Viola⁴  Juan P. Roblero⁵  Luis Colombato⁶  Maria R. Torres-Ibarra⁷  Adriana Varon⁸  Jaime Holguin⁹  Sebastian Marciano^1,10  Hugo Cheinquer^1,11  Henrique Coelho^1,12 

[1] Corresponding author at: AbbVie Inc., 26525 North Riverwoods Boulevard, Mettawa, IL 60045, USA.;AbbVie, Inc., North Chicago, IL, USA;Clinica de Hepatitis, Hospital de Infectologia Centro Medico Nacional La Raza, IMSS, Mexico City, Mexico;Division of Gastroenterology and Hepatology, Sanatorio Güemes, Buenos Aires, Argentina;Division of Gastroenterology, Escola Paulista de Medicina, Universidade Federal de Sao Paulo, Sao Paulo, Brazil;Division of Gastroenterology, Hospital Británico de Buenos Aires, Buenos Aires, Argentina;Division of Hepatology, Centro Mèdico Imbanaco, Cali, Colombia;Facultad de Medicina de la Universidad de Chile, Santiago, Chile;Fundacion Cardioinfantil, Instituto de Cardiologia, Bogatá, Colombia;Liver Unit and Department of Research, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina;Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil;Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil;

关键词: HCV;    LATAM;    Epidemiology;    Observational study;   

DOI  :  

来源: DOAJ

【 摘 要 】

Introduction and objectives: Currently, there are limited data on the epidemiology and disease characteristics of patients with chronic hepatitis C (CHC) in Latin America. The primary objective of this study was to evaluate demographic and disease characteristics of patients with CHC in Latin America. Patients and methods: HEPLA was a non-interventional, multicenter study of the epidemiology and disease characteristics of patients with CHC in Argentina, Brazil, Chile, Colombia, and Mexico. Results: Of the 817 included patients, the median age was 58 years, 53.9% were female, and 39.3% had cirrhosis. Overall, 41.2% were treatment naive, 49.8% were treatment experienced, and 8.9% were currently undergoing treatment. In patients with available data, genotype 1b accounted for 41.6% of infections, followed by genotype 1a (29.9%) and genotype 3 (11.3%). Probable mode of infection was transfusion in 46.8% of patients. Liver-related comorbidities were present in 26.4% of patients and non-liver-related comorbidities were present in 72.3%. Most patients (71.8%) received concomitant medications, with proton-pump inhibitors (20.8%) being the most commonly reported. Conclusions: At the time the HEPLA study was carried out, the data from this cross-section of patients in Latin America showed that the CHC population has variation in disease and viral characteristics, with a minority of patients receiving treatment and many patients having advanced disease. Increased awareness and access to treatment are necessary in Latin America in order to meet the goal of hepatitis C virus elimination by 2030.

【 授权许可】

Unknown